A citation-based method for searching scientific literature

Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
Times Cited: 300

Michèle Rouleau, Anand Patel, Michael J Hendzel, Scott H Kaufmann, Guy G Poirier. Nat Rev Cancer 2010
Times Cited: 892

List of shared articles

Times cited

PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Emily N Risdon, Cindy H Chau, Douglas K Price, Oliver Sartor, William D Figg. Oncologist 2021

PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
Masa Bosnjak, Tanja Jesenko, Bostjan Markelc, Larisa Janzic, Maja Cemazar, Gregor Sersa. Bioelectrochemistry 2021

Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises.
Melissa M Pham, Natalie Y L Ngoi, Guang Peng, David S P Tan, Timothy A Yap. Trends Cancer 2021

DoE Optimization Empowers the Automated Preparation of Enantiomerically Pure [18F]Talazoparib and its In Vivo Evaluation as a PARP Radiotracer.
Gregory D Bowden, Sophie Stotz, Johannes Kinzler, Christian Geibel, Michael Lämmerhofer, Bernd J Pichler, Andreas Maurer. J Med Chem 2021

Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
Junwei Wang, Hui Li, Guangchao He, Zhaoxing Chu, Kewen Peng, Yiran Ge, Qihua Zhu, Yungen Xu. J Med Chem 2020